AMLN (DIABETES DRUGS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: David Bogdanoff who wrote (538)	8/20/1997 11:52:00 AM
From: Richard Belanger	of 2173

David - "Poorly designed study" and "weak clinical program" might be too strong here. It is a fact that the protocol failed to accommodate the increased use of insulin by some of the patients. Do we know yet if the increased use occurred primarily among the placebo group? If so, I would fault the designers less and I would still hold out some hope for "significant" (if not potent) efficacy. More than anything, I think what these results underscore what a complicated disease diabetes is. There's good reason why there hasn't been a new treatment for Type 1 in 75 years! But Wall Street was clearly looking for black and white, and these results will continue to weigh on the stock for some time yet. Rich (shareholder since 6-95)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next